Fuda Cancer Hospital
Gallbladder cancer treatment cost in China is influenced by the disease stage and selected therapy, with proton-beam therapy ranging from $36,500 to $47,500. Surgical resection and chemotherapy are primary options, while advanced proton-beam therapy runs from $36,500 to $47,500. Total expenses depend on hospital tier and the complexity of the multidisciplinary approach. Patients can achieve 40–70% savings compared to the US. Top destinations include Guangzhou, Shanghai, and Xiamen.
Typical Gallbladder Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients find significant value in China’s specialized minimally invasive oncology centers. Fuda Cancer Hospital in Guangzhou is a Joint Commission International (JCI) accredited facility. It offers alternatives to traditional chemotherapy like NanoKnife and cryosurgery. Dr. Liu Shi Xin at Xiamen Humanity Hospital provides precision radiotherapy for abdominal cancers. These experts focus on complex cases that require advanced precision techniques.
| China | Turkey | Austria | |
| Proton-beam therapy | from $36,500 | from $70,000 | from $80,000 |
| Proton therapy for prostate cancer | from $42,500 | from $30,000 | from $80,000 |
| Proton therapy for breast cancer | from $38,500 | from $30,000 | from $55,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Brachytherapy | from $7,200 | from $3,465 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Gallbladder cancer treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Gallbladder cancer treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Gallbladder cancer treatment journey.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Specializing in liver and gallbladder cancer treatment, Leng Yin brings extensive experience from top hospitals in China and Thailand.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.
Gallbladder cancer treatment in China is successful when surgery achieves a total tumor removal. Specialist centers use radical cholecystectomy and liver resection. Advanced clinics also offer cryosurgery and NanoKnife for late-stage cases. JCI-accredited facilities in Guangzhou provide multidisciplinary care for international patients.
Bookimed Expert Insight: Fuda Cancer Hospital has treated over 30,000 international patients using unique minimally invasive protocols. They often apply over 10 different non-surgical therapies for late-stage cases. This specific focus on advanced stages makes it a distinct choice for patients who are ineligible for traditional surgery.
Patient Consensus: Patients note that success depends largely on finding a surgeon with deep experience in biliary procedures. They also emphasize planning for long-term follow-up care as recurrence risk remains a major concern even after successful surgery.
Advanced gallbladder cancer treatments in China focus on precision local destruction and robotic surgery. Specialized centers utilize NanoKnife, cryosurgery, and vascular interventional therapy to treat complex tumors. These minimally invasive options aim to preserve healthy tissue and improve recovery times in high-volume oncology hospitals.
Bookimed Expert Insight: Patient volume is a major quality signal in China. Fuda Cancer Hospital has treated over 30,000 international patients. Large-scale centers often provide specialized techniques like NanoKnife and vascular intervention that are less common elsewhere. Leading specialists like Dr. Leng Yin bring international experience from top hospitals in Thailand. These high-volume facilities often manage advanced cases that other institutions might consider unresectable.
Patient Consensus: Patients emphasize finding a specialized hepatobiliary team rather than a general surgeon. Managing jaundice through biliary stenting is often the first priority to make further treatment possible.
The leading hospitals in China for gallbladder cancer include the Fuda Cancer Hospital in Guangzhou and the Fudan University Shanghai Cancer Center. These centers utilize multidisciplinary teams and advanced technologies like NanoKnife to treat complex cases. Many facilities hold JCI accreditation, ensuring high-quality surgical and oncological care for international patients.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows they treat over 30,000 patients from 100 countries. This high volume of international cases suggests the hospital has refined its logistics for non-residents. Their focus on minimally invasive therapies like vascular interventional therapy provides an alternative when traditional surgery is not possible.
Patient Consensus: Patients often emphasize that finding a surgeon who performs a high volume of gallbladder procedures is vital. They note that traveling to major city centers is necessary to access experienced teams and accurate pathology reviews.
Chinese doctors typically disclose a cancer diagnosis to family members before informing the patient. This cultural practice prioritizes family consensus over individual autonomy. Relatives often decide how much information the patient receives to protect them from emotional distress and maintain hope during treatment.
Bookimed Expert Insight: JCI-accredited facilities like Fuda Cancer Hospital in Guangzhou frequently manage international patients from over 100 countries. These institutions often bridge cultural gaps by offering more direct communication styles than traditional public hospitals. If you prefer full disclosure, specify this during your first meeting with oncologists like Dr. Leng Yin.
Patient Consensus: Patients note that families often request doctors avoid the word cancer entirely. Many recommend bringing a bilingual advocate to ensure the doctor respects the patient's personal preference for direct truth.
Travelers seeking medical care in China primarily require an S-series visa for private affairs. Short-term treatment under 180 days uses the S2 visa. Chronic conditions requiring longer stays or residence permits necessitate the S1 visa. Both require official hospital invitations and certified medical records.
Bookimed Expert Insight: Documentation needs vary significantly based on the intended procedure. For example, specialists like Dr. Leng Yin at Fuda Cancer Hospital treat over 30,000 international patients. This high volume means their administrative teams are familiar with S2 visa invitation requirements. Getting a detailed treatment timeline helps avoid the need for unexpected visa extensions during recovery.
Patient Consensus: Patients warn that standard tourist visas rarely suffice for complex cancer care. They emphasize securing a detailed hospital letter to avoid extra scrutiny at the embassy.
Traditional Chinese Medicine (TCM) is frequently used in China as a supportive therapy alongside standard gallbladder cancer protocols. It never replaces surgery or chemotherapy. Instead, it functions as a complementary tool to manage side effects, improve appetite, and support physical recovery during systemic treatment.
Bookimed Expert Insight: Patients seeking integrative care in China should focus on centers with JCI accreditation like Fuda Cancer Hospital in Guangzhou. While TCM is common, these top-tier facilities prioritize minimally invasive technologies like NanoKnife and cryosurgery for advanced cases. The most effective approach seen in our data is utilizing TCM strictly for rehabilitation after high-tech surgical interventions, rather than as a primary tumor-fighting method.
Patient Consensus: Patients note that TCM helps them tolerate the harshness of chemotherapy by improving sleep and digestion. Many emphasize the importance of disclosure, as some herbs can unexpectedly affect liver enzymes or blood clotting during recovery.